Veracyte Inc - Asset Resilience Ratio
Veracyte Inc (VCYT) has an Asset Resilience Ratio of 3.72% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Veracyte Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Veracyte Inc's Asset Resilience Ratio has changed over time. See VCYT equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Veracyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Veracyte Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.85 Million | 3.72% |
| Total Liquid Assets | $50.85 Million | 3.72% |
Asset Resilience Insights
- Limited Liquidity: Veracyte Inc maintains only 3.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Veracyte Inc Industry Peers by Asset Resilience Ratio
Compare Veracyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Veracyte Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Veracyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.87% | $50.35 Million | $1.30 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $1.11 Billion | -- |
| 2022-12-31 | 2.13% | $24.61 Million | $1.16 Billion | +1.79pp |
| 2021-12-31 | 0.33% | $3.96 Million | $1.19 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $78.67 Million | -- |
| 2016-12-31 | 0.12% | $120.00K | $101.03 Million | -0.04pp |
| 2015-12-31 | 0.16% | $118.00K | $75.28 Million | +0.05pp |
| 2014-12-31 | 0.11% | $70.00K | $64.84 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $79.63 Million | -- |
| 2012-12-31 | 0.26% | $50.00K | $19.07 Million | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more